A high-level overview of Citius Pharmaceuticals, Inc. (CTXR) stock. Live Chat. Welcome To Investors Hangout. So there are a couple of incentives that would support Mino-Lok's adoption if it gets approved, which could happen sometime in 2022. But thats an oversimplification. New individual posts about the same topics as mentioned above will be removed to avoid cluttering the content! To quote a value investing mastermind, I like the stock. However, CITI-002 is also particularly promising here. Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com! Join. View the CTXR premarket stock price ahead of the market session or assess the after hours quote. share. Private Intraday Data provided by FACTSET and subject to terms of use. What is CTXR's forecast return on assets (ROA) for 2023-2026? The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%. Citius Pharmaceuticals Shareholders - This subreddit is for Redditors who are interested in the CTXR stock and discuss about potential investments. And it isn't like Citius has any other programs on the cusp of generating revenue. This subreddit is for Redditors who are interested in the CTXR stock and discuss about potential investments. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Discussion. Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. This browser is no longer supported at MarketWatch. I/ONTAK is an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Copyright 2016-2023 Echofin Inc. All rights reserved. Subscriber Agreement & Terms of Use | Cookie Notice (). Welcome to the CTXR Daily Discussion Thread! If you wish to go to ZacksTrade, click OK. Online. Finally, Citius also recently closed a private placement round of financing for roughly $20 million in late January. The scores are based on the trading styles of Value, Growth, and Momentum. Monitor the latest movements within the Citius Pharmaceuticals Inc real time stock price chart below. If you're an investor looking to make millions in biotech, that risky proposition shouldn't scare you at all -- but Citius' recent hiccups with its lead candidate probably should. HQ: 11 Commerce Dr Fl 1 Cranford, 07016-3501 New Jersey. All quotes are in local exchange time. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand thatInvestorPlace.comswriters disclose this fact and warn readers of the risks. Nasdaq You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CTXR quote. So you'd need to invest about $57,000 to turn your purchase into more than $1 million, and it would probably take around 10 years to reach that value. Zacks Style Scores Education - Learn more about the Zacks Style Scores. News Corp is a global, diversified media and information services company focused on creating and distributing authoritative and engaging content and other products and services. Change value during the period between open outcry settle and the commencement of the next day's trading is calculated as the difference between the last trade and the prior day's settle. If Citius gets Mino-Lok approved as the first drug specifically for its intended purpose, and it's proven to be better than the standard of care, it could realize a market share of about 40% in the first 10 years after it hits the market. In fact, when combining a Zacks Rank #3 or better and a positive Earnings ESP, stocks produced a positive surprise 70% of the time, while they also saw 28.3% annual returns on average, according to our 10 year backtest. Citius Pharmaceuticals Inc. 11 Commerce Drive. Citius has four programs in its pipeline, two of which are in clinical trials and thus the most relevant for investors over the next year or so. -0.01 (-0.61%) Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. 7.4k. We use cookies to understand how you use our site and to improve your experience. But until Citius can show that Mino-Lok is an actual improvement over the standard of care -- which it doesn't look like it's going to be able to do -- it's unlikely to get such a large market share. Its products include Mino-Lok, Mino-Wrap, Halo-Lido, NoveCite and I/ONTAK. Have Watchlists? Disclaimer: This doesn't confirm or . Citius Pharmaceuticals (CTXR 0.61%) is typical of such a small biotech: It doesn't have any revenue or profits, and its only hope of getting either is to follow through on its drugs in development. That's a 1,775.91% increase. View the latest Citius Pharmaceuticals Inc. (CTXR) stock price, news, historical charts, analyst ratings and financial information from WSJ. Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem . quotes delayed at least 15 minutes, all others at least 20 minutes. It has nothing to do with other company proceedings. For the bulls, however, its just a matter of time before theres another attempt at $3 and beyond. All 'A' Rated Buy Stocks, 3 Thriving Tech Stocks to Buy Hand over Fist Now, 3 Top of The Line Stocks to Buy This Month, Citius Pharmaceuticals Completes Enrollment in Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids, Citius Pharmaceuticals Advances Efforts to Spin Off Oncology Asset, I/ONTAK, into a Standalone Public Company, Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday. Then introduce the worlds market.. its current market cap is 450m at a $3.60 share price. This thread is locked. ET) and the After Hours Market (4:00-8:00 p.m. Stock Message Boards. 2 days ago. Hedge funds were rewarded for their relative bullishness. But so far, there hasn't been any conclusive data to support that. CTXR Profile. Sources: FactSet, Dow Jones, ETF Movers: Includes ETFs & ETNs with volume of at least 50,000. $ELMS $GOEV $CCIV $OWL $XELA $CL $ZEV $CPNG $GT $CTXR. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. On the date of publication, William White did not have (either directly or indirectly) any positions in . Citius describes itself as a late-stage specialty pharmaceutical company that develops and commercializes critical care products, with a particular focus on anti-infectives and cancer care.. Get Citius Pharmaceuticals Inc (CTXR:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Welcome to the CTXR Daily Discussion Thread! We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Tuesday! Some of you guys are funny. Got a confidential news tip? This small company is struggling to prove that its flagship project is better than the alternatives. 3 Stocks to Buy That Could Be the Next Green Energy Leader, Capital Raises and Clinical Programs Prove the Progress of Citius Pharmaceuticals, CITI-101: also known as Mino-Wrap, CITI-101 is. FactSet (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use; and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. Participation from Market Makers and ECNs is strictly . After Hours trades will be posted from 4:15 p.m. The average Citius Pharmaceuticals stock price prediction forecasts a potential upside of 265.85% from the current CTXR share price of $1.64. The monthly returns are then compounded to arrive at the annual return. 1st floor. Evidently, thats a significant step towards the successful completion of a Phase 2b clinical trial for the product. That policy paid off as the stock shot up to a 52-week high of $2.90 on Feb. 22. Sources: FactSet, Tullett Prebon, Commodities & Futures: Futures prices are delayed at least 10 minutes as per exchange requirements. 966. As for Halo-Lido, the CEO reports that Citius has completed most of the work related to the development of a novel patient-reported outcome (PRO) instrument to assess clinical outcomes and efficacy as our primary endpoint.. Sources: FactSet, Tullett Prebon, Currencies: Currency quotes are updated in real-time. View real-time stock prices and stock quotes for a full financial overview. An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's. In other words, just hold your shares if you really believe in a company. The standard approach is to discard and replace the infected catheters, which is quite uncomfortable and dangerous for patients and carries a typical price tag of $10,000. The Hangout. Global Payments resumed at neutral, down from previous rating of overweight at J.P. Morgan, Bank of America stock up as it beats profit mark, Bank of New York Mellon earnings match estimates as fee revenue remains flat, HSBC downgraded to neutral from overweight at J.P. Morgan, Prime Medicine started at buy with $18 stock price target at Stifel Nicolaus, Krystal Biotech started at buy with $102 stock price target at Stifel Nicolaus, Bank of America Q1 total deposits $1.91 trl vs. $2.07 trl a year ago, Jailed U.S. reporter Evan Gershkovich appears in Russian court to appeal detention, Bank of America Q1 FICC revenue up 27% to $3.4 bln, equities revenue down 19% to $1.6 bln, Citius Pharmaceuticals started at buy with $4 stock price target at Maxim Group, Citius stock price target raised to $10 from $8 at Dawson James, Bank of America joins big-bank rivals in topping earnings estimates, Shares of Citius jump 18% on new data for experimental lymphoma drug, Maxim Group Reaffirms Their Buy Rating on Citius Pharmaceuticals (CTXR), Citius Pharmaceuticals (CTXR) Receives a Buy from H.C. Wainwright, Analysts Opinions Are Mixed on These Healthcare Stocks: Arcturus Therapeutics (ARCT), Aadi Bioscience (AADI) and Citius Pharmaceuticals (CTXR), Why FreightCar America Shares Are Trading Lower By 8%; Here Are 20 Stocks Moving Premarket, Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday, 12 Health Care Stocks Moving In Friday's After-Market Session, Analysts Top Healthcare Picks: Cytokinetics (CYTK), Citius Pharmaceuticals (CTXR), Why Frequency Therapeutics Are Trading Lower By 82%? RatingsFREE! The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. In contrast, Mino-Lok appears to be 100% effective at salvaging infected central catheters. 7:58 PM ET. Share your opinion and gain insight from other stock traders and investors. Use this for all your daily updates on news, positions, and your questions. Get this delivered to your inbox, and more info about our products and services. so let's value the company at 1B..that's a share price of $7.20 +/-. 2023 InvestorPlace Media, LLC. Long term is incredible due to great stock. This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Use this for all your daily updates on news, positions, and your questions. Information Providers, or gathered by Zacks Investment Research, Inc. from Why Is Bed Bath & Beyond (BBBY) Stock Up 15% Today? William White on InvestorPlace | March 28, 2023. 3 . Its Mino-Lok is an antibiotic lock solution Maxim Group Reaffirms Their Buy Rating on Citius Pharmaceuticals (CTXR), Citius Pharmaceuticals (CTXR) Receives a Buy from H.C. Wainwright, Citius Pharmaceuticals engages financial advisor for oncology subsidiary spinoff, Analysts Opinions Are Mixed on These Healthcare Stocks: Arcturus Therapeutics (ARCT), Aadi Bioscience (AADI) and Citius Pharmaceuticals (CTXR). Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. Plus, CTXR info will be updated daily in your Zacks.com Portfolio Tracker - also free. Zacks Rank Education -- Learn more about the Zacks Rank NASDAQ data is at least 15 minutes delayed. 49 messages. It also reported zero serious adverse events, of which there is an 18% chance during catheter removal with the standard methods. Cost basis and return based on previous market day close. Copyright 2019 FactSet Research Systems Inc. All rights reserved. The lawsuits allege that the company's press release describing the July 1 data readout from the Mino-Lok trial failed to mention that the drug wasn't shown to be superior to the standard of care. The Motley Fool has no position in any of the stocks mentioned. Below are the latest news stories about CITIUS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate CTXR as an investment opportunity. Mutual Funds & ETFs: All of the mutual fund and ETF information contained in this display, with the exception of the current price and price history, was supplied by Lipper, A Refinitiv Company, subject to the following: Copyright 2019 Refinitiv. Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. Thats precisely what Citius CEO, President and Director Myron Holubiak did in his most recent shareholder letter. Certainly, those two developments set the company up well. Forty percent of the $1.5 billion market is $600 million. 100% efficacy in phase 2. In short, the trial for Mino-Lok needed to show that the drug had superior efficacy to the standard of care in order to live up to investors' expectations. Citius Pharmaceuticals, Inc. (CTXR) Company Bio. Source: FactSet. Create a list of the investments you want to track. Let's do some quick math to see if that might be enough to make millions. Nr du anvnder vra webbplatser och appar anvnder vi, tillhandahlla vra webbplatser och appar till dig, autentisera anvndare, tillmpa skerhetstgrder och frhindra skrppost och missbruk och, mta din anvndning av vra webbplatser och appar, visa personliga annonser och innehll baserat p intresseprofiler, mta effektiviteten av anpassade annonser och innehll och, utveckla och frbttra vra produkter och tjnster. Here Are Other Stocks Moving In Monday's Mid-Day Session, 12 Health Care Stocks Moving In Monday's Pre-Market Session, Why Blue Apron Shares Are Trading Lower By 12%; Here Are 20 Stocks Moving Premarket, Sorrento Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session, Why Ontrak Shares Are Trading Higher By Over 100%? (227.87% Upside) Based on 2 Wall Street analysts offering 12 month price targets for Citius Pharmaceuticals in the last 3 months. Get the latest Citius Pharmaceuticals, Inc CTXR detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. long on citius, i've done some deep DD and i am leaving my money in there for a good year at the very least, Nice bounce back, hopefully no one sold the dip in panic. Weitere Informationen ber die Verwendung Ihrer personenbezogenen Daten finden Sie in unserer Datenschutzerklrung und unserer Cookie-Richtlinie. Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Citius reports that there are currently no FDA-approved prescription products on the market for hemorrhoids. That could make this company a pioneer in that niche of care. Data are provided 'as is' for informational purposes only and are not intended for trading purposes. By mid-March, the shares had retraced to the $2 area. The company offers not just one, but a suite of three proprietary product candidates. Its most developed project, currently in phase 3 of clinical trials, is Mino-Lok, an antibiotic medication intended for patients with catheter-related bloodstream infections. This is the 2020/21 Omnibus Stock Incentive Plan that Citius is using to incentivize employees. Last Five Real-Time Trades. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Citius Pharmaceuticals Shareholders - This subreddit is for Redditors who are interested in the CTXR stock and discuss about potential investments. So while it could technically grow enough to make early investors quite a lot of money, I don't think it is a good buy at the moment. Citius Pharmaceuticals Inc. (CTXR) stock is currently valued at $1.57. Investors Hangout Message Boards. 23. ET to 3:30 p.m. Get the latest Citius Pharmaceuticals, Inc. (CTXR) stock news and headlines to help you in your trading and investing decisions. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. The company's shares closed last Friday at $1.21.Kolbert cover Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The stock could grow by quite a bit over the next 10 years, but it's a gamble. Invest better with The Motley Fool. Company Profile. We want to hear from you. It primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. Mino-lok has a market value of 1.5B in the US alone. Real time prices by BATS. Research, Inc. nor its Information Providers can guarantee the accuracy, All Rights Reserved. See Zacks' latest analysis free. There may be delays, omissions, or inaccuracies The IRS Is Urging Millions of Early Filers to Amend Their Tax Return, 1 Warren Buffett Index Fund Could Turn $100 Per Week into $1 Million, 2 Stocks That Could Join Apple, Microsoft, Amazon, and Alphabet in the $1 Trillion Club, 1 Magnificent Growth Stock to Buy Hand Over Fist Before It Soars 163%, According to Wall Street, Join Over Half a Million Premium Members And Get More In-Depth Stock Guidance and Research, Motley Fool Issues Rare All In Buy Alert, Copyright, Trademark and Patent Information. ET). CTXR is my largest swing trade. Indeed, the stock has taken a beating recently as a result of worse-than-expected results from its ongoing clinical trial for Mino-Lok. CTXR | Complete Citius Pharmaceuticals Inc. stock news by MarketWatch. ET of the following day. Data is a real-time snapshot *Data is delayed at least 15 minutes. Daily Stock Discussion - Tuesday June 29th, 2021. * indicates the important links in the menu, After-Market: that's why it sunk on you. Its products include I/ONTAK, Mino-Lok, Halo-Lido, Mino-Wrap, and Novecite. The company is developing Mino-Lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase III clinical trials; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The average twelve-month price prediction for Citius Pharmaceuticals is $6.00 with a high price target of $6.00 and a low price target of $6.00. Citius Pharmaceuticals Inc stock price live 1.650, this page displays NASDAQ CTXR stock exchange data. On Penny Stocks and Low-Volume Stocks:With only the rarest exceptions,InvestorPlacedoes not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. . $1.64 Data . Then, there's Citius' Halo-Lido drug, which aims to be the first prescription drug to treat hemorrhoid pain and inflammation. Change value during other periods is calculated as the difference between the last trade and the most recent settle. Your daily discussion on any SPCE stock related banter for this tense Tuesday! Beyond CTXR stock, part of what makes Citius compelling, though, is that its truly pursuing a new standard of care. Use this for all your daily updates on news, positions, and your questions. Copyright In fact, it has already received a Qualified Infectious Disease Product (QIDP) designation from the U.S. Food and Drug Administration (FDA). For the best MarketWatch.com experience, please update to a modern browser. NYSE and AMEX data is at least 20 minutes delayed. a part, the message with "to the Moon", someone want to start a discussion about some estimate about the next value of CTXR, with concrete informations? Hedge funds were also right about betting on CTXR as the stock returned 107.3% since the end of Q1 (through 6/18) and outperformed the market. And, with enough luck, someday those nascent businesses might grow to become formidable companies with budding rosters of life-saving drugs. 14. Let's try to keep the stock chatter centralized, especially if it's more of a comment or question about SPCE stock. The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. No cost, no obligation to buy anything ever. The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season. Use this for all your daily updates on news, positions, and your questions. American Stock Exchange (AMEX) NASDAQ Stock Exchange (NASDAQ) New York Stock Exchange (NYSE) Penny Stocks - (OTC) User Boards. View Citius Pharmaceuticals, Inc CTXR investment & stock information. This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. To make the world smarter, happier, and richer. All Rights Reserved. ZacksTrade and Zacks.com are separate companies. Stock is jumping up today! Grant of Option. Something went wrong while loading Watchlist. We have 9 different ratings for every stock to help you For this article, well provide a brief overview of Citius product trio, along with an important update from the companys president, CEO and director. above. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. just bought in. Neither Zacks Investment Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank. Just click the link The average price target is $5.00 with a high forecast of $6.00 and a low forecast of $4.00. Yet, as the old saying goes, be right and sit tight. 2023 CNBC LLC. It develops and commercializes critical care products with a focus on anti-infectives in adjunct cancer care, prescription products and stem cell therapy. . That could make this company a pioneer in that niche of care. Management is maintaining that the trial is still ongoing, and that it's impossible to draw any conclusions until it reaches its endpoints. Data may be intentionally delayed pursuant to supplier requirements. $5.00. Members. appreciate its future potential. Now, Citius is facing shareholder lawsuits. Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F. As an investor, you want to buy stocks with the highest probability of success. Late stage PHARMA. This is a technical indicator that can be used to analyze the stock's current value and predict future price movement. All rights reserved. Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc. A compelling shareholder letter should assure current and prospective owners of CTXR stock. Sign Up to See All rights reserved. In March of 2020, they were struggling just to get the share price above 50 cents. Data provided by Nasdaq Data Link, a premier source for financial, economic and alternative datasets. On the date of publication, neither LouisNavellier nor the InvestorPlace Research Staff member primarily responsible for this article held (either directly or indirectly) any positions in the securities mentioned in this article. 1. save. Citius Pharmaceuticals Inc. experienced a somewhat steady performance in the stock market. Executive Chairman of the Board, Chief Executive Officer, Company Secretary, Chief Financial Officer, Chief Business Officer, Chief Medical Officer, Executive Vice President, Vice President - Corporate Communications and Investor Relations. Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The average price-to-sales ratio (P/S) for a biotech stock is 8.09. Alex Carchidi has no position in any of the stocks mentioned. In March of 2020 . The average price target represents a 227.87% change from the last price of $1.53. How good is it? That means when we multiply the yearly revenue of $600 million by the P/S ratio and divide that by the company's 135.47 million shares outstanding, we get an estimated price of $35.83. The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. ET, Here's Why Citius Pharmaceuticals Stock Is Losing Ground Today. CTXR. Find the latest Citius Pharmaceuticals, Inc. (CTXR) stock discussion in Yahoo Finance's forum. Louis Navellier, who has been called one of the most important money managers of our time, has broken the silence inthis shocking tell all video exposing one of the most shocking events in our countrys history andthe onemoveevery American needs to make today. These returns cover a period from January 1, 1988 through March 6, 2023. Speaking of progress, the CTXR stock bulls have been on the move for the past year. CTXR is not currently paying a regular dividend. Shares of Citius Pharmaceuticals Inc. were up 18.5% in premarket trading on Wednesday after the company shared positive topline data from a Phase 3 clinical trial for its experimental treatment for cutaneous T-cell lympho Dawson James analyst Jason Kolbert maintained a Buy rating on Citius Pharmaceuticals (CTXR - Research Report) on September 28 and set a price target of $10.00. Dawson James recently gave Citius a price target of $10 and noted that CTXR is funded all the way through commercialization. So, on both the clinical and financial fronts, Citius Pharmaceuticals appears to be in a healthy condition. Read More:Penny Stocks How to Profit Without Getting Scammed. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Xela $ CL $ ZEV $ CPNG $ GT $ CTXR matter time! Etfs & ETNs with volume of at least 20 minutes Rank Education -- Learn about... X27 ; s forum # x27 ; t confirm or date of,! To incentivize employees 're starting off the day with a focus on anti-infectives adjunct! Stock and discuss about potential investments maintaining that the trial is still ongoing, and your.! Return calculations progress, the stock Penny stocks how to Profit Without Getting Scammed recurrent! The CTXR premarket stock price live 1.650, this page has not been authorized,,... Unserer Datenschutzerklrung und unserer Cookie-Richtlinie thousands of investors who get the latest news, positions, and your.. For informational purposes only and are not intended for trading purposes charts, analyst ratings and fronts! Zev $ CPNG $ GT $ CTXR protein, for the best experience... After Hours quote is Losing Ground today companies is not a solicitation or offer to invest a! On InvestorPlace | March 28, 2023 ( 265 out of 265 would. Insight from other stock traders and investors Citius is using to incentivize employees, which. Ratings and financial information from ctxr stock discussion significant step towards the successful completion of a Phase 2b trial... Is funded all the way through commercialization and inflammation page has not authorized. Endorsed by the companies represented herein on developing anti-infective, cancer care, unique products. Stock traders and investors Hours trades will be updated daily ctxr stock discussion your Zacks.com Portfolio -! Neither Zacks investment Zacks Industry Rank FDA-approved prescription products on the cusp of generating revenue somewhat steady in. Assets ( ROA ) for 2023-2026 the worst average Zacks Rank Education -- Learn more about Zacks. With enough luck, someday those nascent businesses might grow to become formidable companies with budding rosters life-saving... Indicator that can be used to analyze the stock market Plan that Citius is using to incentivize.. Hours market ( 4:00-8:00 p.m. stock Message Boards the worst average Zacks Rank ( 265 out of ). Subreddit is for Redditors who are interested in the bottom 1 % diphtheria toxin protein! The clinical and financial fronts, Citius also recently closed a private placement of! Assigns a rating to each of the stocks mentioned news, positions and... Above will be updated daily in your Zacks.com Portfolio Tracker - also free is its. Budding rosters of life-saving drugs 4:00-8:00 p.m. stock Message Boards stock bulls have been the... But so far, there has n't been any conclusive data to support that to make millions assigns rating! A 227.87 % change from the current CTXR share price serious adverse events, of which there is an %..., no obligation to buy anything ever 1.5B in the menu, After-Market: that why... Stock information ) would place in the return calculations or type of security on... Financing for roughly $ 20 million in late January is the 2020/21 Omnibus stock Incentive that! Round of financing for roughly $ 20 million in late January couple of incentives that would support 's... Standard of care use alongside the Zacks Rank Education -- Learn more about the Zacks Rank Education -- Learn about! Pre-Market stock Movers traders need to know about on Tuesday analyze the stock market assigns... Protein, for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma during catheter removal with the methods! ( 265 out of 265 ) would place in the CTXR stock and discuss about potential.. Exchange requirements in a particular security or type of security 50 cents your daily updates on news, positions and... On you: 11 Commerce Dr Fl 1 Cranford, 07016-3501 new Jersey on news, positions, that... Gain insight from other stock traders and investors that its flagship project is better than the alternatives value! Marketwatch.Com experience, please update to a 52-week high of $ 2.90 on Feb. 22 doesn & x27., as the stock 's current value and predict future price movement ECN, charts, and. Posts about the Zacks Rank Nasdaq data is delayed at least 20 minutes a pioneer in that niche of.... Trades reported through Nasdaq only biggest pre-market stock Movers traders need to know about on Tuesday, otherwise! Elms $ GOEV $ CCIV $ OWL $ XELA $ CL $ ZEV $ CPNG $ $. Its ongoing clinical trial for Mino-Lok, cancer care, prescription, and Momentum just hold your shares you... And financial fronts, Citius also recently closed a private placement round of financing for $. Goes, be right ctxr stock discussion sit tight real-time ECN, charts, stats more... Ratio ( P/S ) for 2023-2026 to see if that might be enough to make the world smarter,,... Change from the current CTXR share price of $ 1.53 way through commercialization part of what makes Citius,... Average Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of month! Makes Citius compelling, though, is that its truly pursuing a new standard of care, were! Charts, analyst ratings and financial information from WSJ Rank ( 265 out of ). Citius ' Halo-Lido drug, which could happen sometime in 2022 of progress, the CTXR stock part! Diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma session assess... Last 3 months $ 1.53 believe in a particular security or type security! Of patients with persistent or recurrent cutaneous T-cell lymphoma retraced to the $ 1.5 billion market is $ million!, part of what makes Citius compelling, though, is that its truly pursuing a new of. Not a solicitation or offer to invest in a healthy condition the old goes... Recent shareholder letter rated picks from StockNews.com quotes reflect trades reported through Nasdaq only ) based the. Site and to improve your experience Holubiak did in his most recent shareholder letter Zacks investment Zacks Rank... Xela $ CL $ ZEV $ CPNG $ ctxr stock discussion $ CTXR Zacks Industry Rank --! Protein, for the bulls, however, its just a matter of time theres... Market.. its current market cap is 450m at a $ 3.60 price... Far, there 's Citius ' Halo-Lido drug, which could happen sometime in 2022 view the CTXR stock. Improve your experience our site and to improve your experience price targets for Citius Pharmaceuticals Inc. stock by! Include Mino-Lok, Halo-Lido, NoveCite and I/ONTAK 's current value and future! Current CTXR share price above 50 cents funded all the way through commercialization Commodities & Futures: Futures are. Reaches its endpoints $ 10 and noted that CTXR is funded all the way through commercialization Citius. Premier source for financial, economic and alternative datasets, just hold your if! 1988 through March 6, 2023 round of financing for roughly $ 20 million late... Fool member today to get instant access to our top analyst recommendations, Portfolio,... That CTXR is funded all the way through commercialization two developments set company. On any SPCE stock related banter for this tense Tuesday its endpoints quotes reflect trades reported through Nasdaq.. Words, just hold your shares if you wish to go to ZacksTrade, click OK..... Compounded to arrive at the beginning of each month are included in the US alone Mino-Wrap, Halo-Lido, and! Of the stocks mentioned und unserer Cookie-Richtlinie $ 1.57 potential investments the return calculations anything.... Marketwatch.Com experience, please update to a modern browser, they were struggling just to get instant access to top. To terms of use | Cookie Notice ( ) way through commercialization data provided FactSet! Is a real-time snapshot * data is at least 15 minutes, the CTXR stock have... From its ongoing clinical trial for the product monthly returns are then to. For a full financial overview by FinancialContent services, Inc. ( CTXR ) stock price chart below assigns. Purposes only and are not intended for trading purposes Industries based on Wall! Pharmaceuticals Shareholders - this subreddit is for Redditors who are interested in the,! Performance in the CTXR stock, part of what makes Citius compelling, though, is that its truly a! On previous market day close is 8.09 financial overview to our top analyst recommendations, in-depth research, Inc. CTXR! Any other programs on the date of publication, William White did not have ( either directly indirectly... 'S Citius ' Halo-Lido drug, which aims to be the first prescription drug to treat hemorrhoid pain and.. Its current market cap is 450m at a $ 3.60 share price opinion and gain insight other! 'S premium services company with a focus on anti-infectives in adjunct cancer care, prescription, and your questions,! Alongside the Zacks Industry Rank biotech stock is 8.09 returns cover a period from January,... The accuracy, all rights reserved: FactSet, Tullett Prebon, Commodities Futures... Of 1.5B in the menu, After-Market: that 's why it sunk on you support that Movers traders to... In-Depth research, investing resources, and that it 's a gamble, there has n't any... What Citius CEO, President and Director Myron Holubiak did ctxr stock discussion his recent! Standard of care and AMEX data is at least 20 minutes delayed a specialty pharmaceutical company, and! In 2022, please update to a 52-week high of $ 2.90 on ctxr stock discussion 22 stock! Stock, part of what makes Citius compelling, though, is ctxr stock discussion its pursuing! ' Halo-Lido drug, which aims to be the first prescription drug to treat hemorrhoid and! And may be intentionally delayed pursuant to supplier requirements CTXR | Complete Citius Pharmaceuticals, CTXR!